ערך בספרים למניה: kalarx.com (KALA)

KALA BIO, Inc. (KALA) is actively implementing stem cell technologies to develop advanced corneal restoration methods. The asset's price trajectory shown below complements data on clinic partnerships aimed at accelerating the commercialization of new formulas. The current metric stands at 0.47. The business's financial performance is based on the sale of patented anti-inflammatory drops and innovative treatments for ocular pathologies.

This indicator reflects the net asset value of KALA BIO, Inc. minus all liabilities, allocated per share, allowing for an assessment of the business's intrinsic value. The trend in book value per share demonstrates the financial stability of KALA BIO, Inc. as it develops innovative secretome-based corneal regeneration drugs, confirming the availability of solid capital to execute its research and development programs.